登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301103 证券简称：何氏眼科 公告编号：2025-053 辽宁何氏眼科医院集团股份有限公司关于股东回馈活动的自愿性信息披露公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）成立三十周年之际，为建立长效、多样的股东 回报机制，感谢广大股东长期以来对公司的关注和支持，为感谢投资者的长期信任，进一步形成传播眼 健康、全民眼健康的良好氛围，公司开展"投资者健康回馈活动"，现将本次活动内容公告如下： 一、活动内容 1、医院为每位参与活动的股东配备专属眼健康服务顾问，提供 "全流程便捷服务"； 2、视光产品类优惠：角膜塑形镜、近视管理镜片、框架眼镜等； 3、诊疗项目专属优惠：眼脑视觉训练、基因检测项目、睑板腺按摩治疗等； 4、近视矫正屈光手术股东专属优惠； 5、医美项目； 6、眼健康检查专属方案。 二、参加活动的股东范围 包括现有股东、历史股东及未来投资者，股东本人及直系亲属（配偶、父母、子女）。 五、参与方式 ■ 更多活动细节，通过微信搜索 "何氏眼科 ...

Core Viewpoint - He Eye Hospital (301103.SZ) is celebrating its 30th anniversary by launching an "Investor Health Feedback Activity" to establish a long-term and diverse shareholder return mechanism, expressing gratitude to shareholders for their ongoing support and trust [1] Group 1: Investor Engagement - The company will provide each participating shareholder with a dedicated eye health service consultant to offer "full-process convenient services" [1] - Discounts will be available on optical products such as orthokeratology lenses, myopia management lenses, and frame glasses [1] - Exclusive discounts on diagnostic projects including eye-brain visual training, genetic testing, and meibomian gland massage therapy will be offered [1] Group 2: Surgical and Aesthetic Services - Shareholders will receive exclusive discounts on myopia correction refractive surgeries [1] - Aesthetic medical projects will also be included in the offerings [1] - Special eye health check-up plans will be available for shareholders [1]

格隆汇12月26日丨何氏眼科(301103.SZ)公布，公司成立三十周年之际，为建立长效、多样的股东回报 机制，感谢广大股东长期以来对公司的关注和支持，为感谢投资者的长期信任，进一步形成传播眼健 康、全民眼健康的良好氛围，公司开展"投资者健康回馈活动"。活动内容：1、医院为每位参与活动的 股东配备专属眼健康服务顾问，提供"全流程便捷服务"；2、视光产品类优惠：角膜塑形镜、近视管理 镜片、框架眼镜等；3、诊疗项目专属优惠：眼脑视觉训练、基因检测项目、睑板腺按摩治疗等；4、近 视矫正屈光手术股东专属优惠；5、医美项目；6、眼健康检查专属方案。 ...

继完成对新产业眼科的全资控股后，昊海生科再次出手。昊海生科近日发布公告称，拟以自有资金 3835.15万元受让苗九昌、苗春云合计持有的江西瑞济生物工程技术股份有限公司（以下简称"瑞济生 物"）846.61万股股份，占瑞济生物总股本的19.8%，借此切入生物羊膜这一高价值医疗器械赛道。值得 关注的是，瑞济生物虽深耕羊膜产品领域多年，但近年业绩持续承压，去年及今年前三季度分别亏损 1176.61万元和1129.37万元，同时，本次交易未设置任何业绩承诺或对赌安排，亦潜藏不小的投资损失 风险。 收购背后，是昊海生科主营业务的增长困境。作为全国首家"港股+科创板"生物医药上市公司，其今年 业绩持续下滑，上半年营收、净利润同比降幅7.12%和10.29%，医美、眼科、骨科等核心业务全线承 压。 目标公司连续亏损 公开资料显示，瑞济生物成立于2002年，2016年于新三板挂牌，并于今年4月退市。公司主营生物羊膜 的生产与销售，主要产品包括凹凸羊膜、生物骨科羊膜、湿态生物羊膜等，属于国家三类医疗器械，主 要用于骨科和眼科领域的组织修复。 根据新思界产业研究中心的报告，瑞济生物曾一度为中国唯一具备羊膜生产资质的企业，垄断该产 ...

收购背后，是昊海生科主营业务的增长困境。作为全国首家"港股+科创板"生物医药上市公司，其2025 年业绩持续下滑，上半年营收、净利润同比降幅7.12%和10.29%，医美、眼科、骨科等核心业务全线承 压。 继完成对新产业眼科的全资控股后，昊海生科又出手了。12月12日晚间，昊海生科发布公告称，公司拟 以自有资金3835.15万元受让苗九昌、苗春云合计持有的江西瑞济生物工程技术股份有限公司（以下简 称"瑞济生物"）846.61万股股份，占瑞济生物总股本的19.8%，借此切入生物羊膜这一高价值医疗器械 赛道。值得关注的是，瑞济生物虽深耕羊膜产品领域多年，但近年业绩持续承压，2024年及2025年前9 个月分别亏损1176.61万元、1129.37万元，同时，本次交易未设置任何业绩承诺或对赌安排，亦潜藏着 不小的投资损失风险。 核心业务承压 目标公司连续两年亏损 公开资料显示，瑞济生物成立于2002年，2016年于新三板挂牌，并于今年4月退市。公司主营业务为生 物羊膜的生产与销售，主要产品包括凹凸羊膜、生物骨科羊膜、湿态生物羊膜等，属于国家三类医疗器 械，主要用于骨科和眼科领域的组织修复。 根据新思界产业研究中心的 ...

证券日报网讯12月10日，何氏眼科（301103）在互动平台回答投资者提问时表示，公司在智能化系统眼 科应用方面，整合了智能算法辅助诊断系统，建设眼科专科智能影像云平台，开发多模态数据融合决策 系统，并生成3D眼健康数字孪生模型。通过深度算法助力健康管理，"何氏糖管家"基于智能技术中的 深度学习算法，利用动态血糖监测设备，实时监测并传输血糖级别至云端，通过云端数据分析、医患交 互平台及个性化健康管理方案，旨在实现糖尿病患者全生命周期的精准控糖与眼病防控。此外何氏眼 科"光明小屋"以眼科智能设备为入口，结合线上和线下的眼科诊疗系统，通过先进的智能诊断，发现眼 部疾病和慢性疾病，打造数字智能技术赋能基层眼健康管理的数字场景。在角膜塑形镜验配领域，公司 基于智能算法建立了VST设计的算法模型，通过深度学习提高验配效率。以上业务对公司当前主营业务 开展或业绩未造成重大影响，如有重大进展或者触及信息披露标准，会按照监管要求履行信息披露义 务，敬请谨慎决策、注意投资风险。 ...

中国科学技术大学校园风景。 新华社图 "倾城之恋" "九州治世赖精方，六艺交融助国昌；科字当头辟新径，学承妙术焕荣光。"这首出自96级校友的诗，被 镌刻在中国科学技术大学（简称"科大"）郭沫若广场上铺设的铜铸"班级地砖"上，饱含往届校友科技报 国的决心和对学校的深情。 1958年，基于国家"两弹一星"事业的发展和对尖端科技人才的迫切需要，科大应运而生。"国运所系"之 背景下，钱学森、郭永怀、赵九章、华罗庚等一大批国内最有声望的科学家登台任教，目的是把最新成 果和前沿知识及时传授给肩负国家使命的学生们。 时光流转，2025年11月公布的"两院"院士增选名单中，有5位"科大人"当选。 科技之花结出产业之果，投射到今日的资本市场上，根据科大校友总会公开的上市校友企业数据，包括 寒武纪、迈瑞医疗、中微公司、科大讯飞、凯赛生物、国盾量子等在内的"科大系"（基于科大校友创立 或科大科技成果转化孵化的公司）31家A股上市公司中，超半数在科创板上市。除寒武纪外的30家"科 大系"公司平均市值295亿元，注册地在安徽的7家"科大系"A股上市公司对区域板块市值贡献率超过 7.6%。 技术驱动，是科大创业者身上的共性标签。上海证券 ...

Core Viewpoint - A joint venture company, Hefei Opu Sanyang Technology Co., Ltd., which was once highly anticipated in the market, is quietly heading towards termination less than two years after its establishment [1] Company Overview - Hefei Opu Sanyang Technology Co., Ltd. was established in August 2023 with a registered capital of 30 million RMB, focusing on the sales of medical devices and consumer health products [4] - The company was a collaboration between Opu Kangshi Technology Co., Ltd., Hefei Sanzhi Yang Network Technology Co., Ltd., and individual shareholder Zhao Chunsheng [4] Strategic Collaboration - The joint venture aimed to combine Opu Kangshi's strengths in eye health product development and offline services with Sanzhi Yang's online sales channels to expand the market for consumer eye health products [4] - Initial product offerings included colored contact lenses, regular soft contact lenses, lens care solutions, eye masks, and eye patches, with plans for future product additions [4] Market Impact - The collaboration attracted significant investor attention and market debate, but Opu Kangshi's stock price experienced a notable decline on the first trading day following the announcement of the joint venture [6] - Sanzhi Yang's online presence included 500,000 to 1 million live viewers during broadcasts, nearly 200 million total followers, and daily sales exceeding 100 million RMB [5] Regulatory Challenges - The partnership faced scrutiny when Sanzhi Yang Network was penalized for false advertising related to various products, resulting in fines totaling approximately 68.95 million RMB and compensation exceeding 27 million RMB [7] - Opu Kangshi was also affected by the negative publicity surrounding Sanzhi Yang, leading to investor concerns and inquiries about the collaboration [7] Industry Context - The rise of digital technology and new business models has created growth opportunities, but issues such as traffic prioritization and algorithm misuse pose risks to the healthy development of the platform economy [8] - The State Administration for Market Regulation has issued guidelines to promote compliance among online trading platforms and enhance market order [8]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 80 yuan [2][6]. Core Views - The company experienced a phase of performance pressure in 2025, with a revenue of 1.144 billion yuan (up 6.43%) and a net profit of 290 million yuan (down 8.64%) for the first three quarters [2]. - The company is accelerating its innovation and research and development efforts, with significant product launches expected to contribute to future growth [2][6]. Financial Performance Summary - **Revenue and Profitability**: - For Q3 2025, revenue was 358 million yuan (down 8.17%), and net profit was 77 million yuan (down 29.85%) [2]. - The projected total revenue for 2024A is 1.41 billion yuan, with a growth rate of 48.2%, and expected to reach 2.34 billion yuan by 2027E [7]. - **Profit Forecast**: - The forecasted net profit for 2025E is 394 million yuan, with a growth rate of 1.5%, increasing to 571 million yuan by 2027E [7]. - **Earnings Per Share (EPS)**: - The EPS is projected to be 2.01 yuan for 2024A, increasing to 2.95 yuan by 2027E [7]. Product and Market Insights - **Product Performance**: - The artificial lens and contact lens businesses faced temporary pressure due to market conditions, while the orthokeratology lens business showed robust growth [2][6]. - **Innovation and R&D**: - The company has launched two significant products in 2025, which are expected to enhance its market position and sales potential [2][6]. Valuation and Market Position - **Valuation Metrics**: - The company is valued at approximately 155 billion yuan, with corresponding price-to-earnings (PE) ratios projected at 29, 24, and 20 for the years 2025E, 2026E, and 2027E respectively [2][6]. - **Market Capitalization**: - The total market capitalization is reported at 11.633 billion yuan [3].

Group 1 - The core viewpoint of the articles highlights the Chinese government's initiatives to promote the high-quality development of the medical device industry through various supportive measures and regulatory reforms [1][2]. - Beijing's measures include 15 supportive actions aimed at enhancing clinical research, registration, production, application, and international expansion of innovative medical devices [1]. - Shanghai's measures focus on expediting the registration process for innovative Class II medical devices, aiming to reduce the average registration cycle to within six months [1][2]. Group 2 - The "14th Five-Year Plan" emphasizes support for the development of innovative drugs and medical devices, indicating a robust growth trajectory for China's medical industry [2]. - The medical device market in China is projected to grow from 729.8 billion RMB in 2020 to 941.7 billion RMB by 2024, with a compound annual growth rate (CAGR) of 6.6%, and is expected to reach 1.81 trillion RMB by 2035 [2]. - The A-share market for medical devices has a total market capitalization of 1.38 trillion RMB, with major companies like Mindray Medical and United Imaging Healthcare leading the sector [3]. Group 3 - There are 45 medical device stocks with a rolling price-to-earnings (P/E) ratio below 40, including 12 stocks with a P/E ratio below 20, indicating potential undervaluation in the sector [4]. - As of November 25, 20 stocks have seen a price decline of over 20% from their yearly highs, with five stocks experiencing declines exceeding 30% [4]. - Aibo Medical, a leading manufacturer of high-end artificial lenses, reported a net profit of 290 million RMB for the first three quarters, a year-on-year decrease of 8.64%, but anticipates steady growth in sales by 2026 [4].